CM
TEVA icon

Castleark Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Castleark Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,700
Closed -$118K – 443
2017
Q3 		$118K Buy
+6,700
New +$151K ﹤0.01% 370
2016
Q3 		– Sell
-2,480
Closed -$125K – 411
2016
Q2 		$125K Buy
+2,480
New +$132K ﹤0.01% 344

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Castleark Management's TEVA Position: Q4 2017 in Review

Castleark Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2017, closing a stake of 6,700 shares — an estimated $118K sold.

Castleark Management first reported a position in TEVA in Q2 2016 and held it in 2 quarters. The position peaked at $125K in Q2 2016. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Castleark Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2017 after selling out during the quarter.
  • Castleark Management sold 6,700 Teva Pharmaceutical Industries Limited shares in Q4 2017, an estimated $118K.
  • Castleark Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2016 and held it in 2 quarters.
  • Castleark Management's Teva Pharmaceutical Industries Limited position peaked at $125K in Q2 2016.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2017.

Based on Castleark Management's 13F filing for Q4 2017, filed 15 Feb 2018.